Managing the toxicity of hematopoietic stem cell transplant

Journal of Supportive Oncology

Volumn 2, Issue 3, 2004, Pages 223-237

  Pallera, Arnel M ^a,b   Schwartzberg, Lee S ^b  

^a WEST CLINIC   (United States)

^b Baptist Centers for Cancer Care Stem Cell Transplant Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; AMPHOTERICIN B; ANTITHROMBIN III; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFIBROTIDE; FLUCONAZOLE; FOSCARNET SODIUM; GANCICLOVIR; GLUTAMINE; HAEMOPHILUS INFLUENZAE VACCINE; HEPARIN; HERPES ZOSTER IMMUNOGLOBULIN; HYDROMORPHONE; IFOSFAMIDE; IMMUNOGLOBULIN; INFLUENZA VACCINE; KERATINOCYTE GROWTH FACTOR; MORPHINE; PALIFERMIN; PILOCARPINE; RIBAVIRIN; RITUXIMAB; TACROLIMUS; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD CLOTTING DISORDER; BLOOD DONOR; BONE MARROW TRANSPLANTATION; BRAIN HEMATOMA; CANDIDA; CARDIOMYOPATHY; CARDIOTOXICITY; CEREBRAL SINUS THROMBOSIS; CLINICAL TRIAL; COLITIS; CYTOMEGALOVIRUS INFECTION; DIARRHEA; ENDOCARDITIS; ESOPHAGITIS; FEVER; GASTROINTESTINAL TOXICITY; GRAFT VERSUS HOST REACTION; HAEMOPHILUS INFLUENZAE TYPE A; HEART DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATURIA; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC CYSTITIS; HERPES SIMPLEX; HERPES ZOSTER; HLA TYPING; HUMAN; HYPERAMMONEMIA; HYPERTENSION; KIDNEY DISEASE; LIVER HEMORRHAGE; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; MENTAL DISEASE; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROLOGIC DISEASE; NUTRITIONAL DEFICIENCY; PERICARDITIS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCYSTIS CARINII; POLYNEUROPATHY; PROTEINURIA; PROTOZOAL INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; UMBILICAL CORD BLOOD; VARICELLA ZOSTER VIRUS; VOMITING; WERNICKE ENCEPHALOPATHY; DISEASE MANAGEMENT; GASTROINTESTINAL DISEASE; LIVER DISEASE; LUNG DISEASE; MALNUTRITION; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM; RISK FACTOR; SURGICAL INFECTION;

DISEASE MANAGEMENT; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MALNUTRITION; PERIPHERAL NERVOUS SYSTEM; RISK FACTORS; SURGICAL WOUND INFECTION;

EID: 4644362895     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Sullivan KM, Dykewicz CA, Longworth DL, et al. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology 2001:392-421.
2. Elishoov H, Or R, Strauss N, Engelhard D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients: a 5-year prospective study. Medicine (Baltimore) 1998;77:83-101.
3. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-851.
4. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis 1995;171:1545-1552.
5. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63-67.
6. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984;100:823-828.
7. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 1995;86:3598-3603.
8. Bacigalupo A, van Lint MT, Tedone E, et al. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir. Bone Marrow Transplant 1994;13:753-758.
9. van Burik JA, Weisdorf DJ. Infections in recipients of blood and marrow transplantation. Hematol Oncol Clin North Am 1999;13:1065-1089.
10. Koc Y. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-49.
11. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000;25:751-755.
12. Gross TG, Loechelt BJ. Epstein-Barr virus associated disease following blood or marrow transplant. Pediatr Transplant 2003;7(suppl 3):44-50.
13. McLeod BC.Thrombotic microangiopathies in bone marrow and organ transplant patients. J Clin Apheresis 2002;17:118-123.
14. Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer 2000;8:33-39.
15. Wardley AM, Jayson GC, Swindell R, et al. Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue. Br J Haematol 2000;110:292-299.
16. Spielberger R, Emmanouilides C, Stiff P, et al. Use of recombinant human keratinocyte growth factor (rHuKGF) can reduce severe oral mucositis in patients (pts) with hematologic malignancies undergoing autologous peripheral blood progenitor cell transplantation (auto-PBPCT) after radiation-based conditioning: results of a phase 3 trial. In: Program/Proceedings of the 39th Annual Meeting of the American Society of Clinical Oncology; May 31-June 3, 2003; Chicago, III. Abstract 3642.
17. Awidi A, Homsi U, Kakail RI, et al. Double-blind, placebo-controlled cross-over study of oral pilocarpine for the prevention of chemotherapy-induced oral mucositis in adult patients with cancer. Eur J Cancer 2001;37:2010-2014.
18. da Fonseca MA. Management of mucositis in bone marrow transplant patients. J Dent Hyg 1999;73:17-21.
19. Sonis ST, Oster G, Fuchs H, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 2001;19:2201-2205.
20. Muscaritoli M, Grieco G, Capria S, Iori AP, Rossi Fanelli F. Nutritional and metabolic support in patients undergoing bone marrow transplantation. Am J Clin Nutr 2002;75:183-190.
21. Sax HC. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation: a randomized, double-blind, controlled study.J Parenter Enteral Nutr 1992;16:589-590.
22. Clarkson J, Worthington HV, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment [Cochrane Review]. In: The Cochrane Library, Issue 4, 2003. Chichester, UK:John Wiley & Sons;2003.
23. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
24. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;5:306-315.
25. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-1736.
26. Vogelsang GB, Dalal J. Hepatic venoocclusive disease in blood and bone marrow transplantation in children: incidence, risk factors,and outcome.J Pediatr Hematol Oncol 2002;24:706-709.
27. Richardson PG, Murakami C, Jin Z, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-4343.
28. Ho VT, Soiffer RJ. The history and future ofT-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 2001;98:3192-3204.
29. Flowers ME, Kansu E, Sullivan KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999;13:1091-1112.
30. Lazarus HM,Vogelsang GB,Rowe JM. Prevention and treatment of acute graft-versus-host disease: the old and the new: a report from the Eastern Cooperative Oncology Group (ECOG). Bone Marrow Transplant 1997;19:577-600.
31. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells 1996;14:473-489.
32. Atkinson K, Horowitz MM, Gale RP, et al. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 1990;75:2459-2464.
33. Goker H, Haznedaroglu IC, Chao NJ. Acute graft-vs-host disease: pathobiology and management. Exp Hematol 2001;29:259-277.
34. Carpenter PA, Sanders JE. Steroid-refractory graft-vs.-host disease:past,present and future.Pediatr Transplant 2003;7(suppl 3):19-31.
35. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196-1201.
36. Lee SJ,Vogelsgang G,Flowers ME.Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-233
37. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation.Chest 1996;109:1066-1077.
38. Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD.Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-788.
39. Clark JG, Hansen JA, Hertz MI, Parkman R, Jensen L, Peavy HH. NHLBI workshop summary: idiopathic pneumonia syndrome after bone marrow transplantation. Am Rev Respir Dis 1993;147(6 pt 1):1601-1606.
40. Robbins RA, Linder J, Stahl MG, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989;87:511-518.
41. Metcalf JP, Rennard SI, Reed EC, et al. Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation. Am J Med 1994;96:327-334.
42. Ho VT, Weller E, Lee SJ, Alyea EP, Antin JH, Soiffer RJ. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7:223-229.
43. Chen CS, Boeckh M, Seidel K, et al. Incidence, risk factors,and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 2003;32:515-522.
44. Marras TK, Szalai JP, Chan CK, Lipton JH, Messner HA, Laupacis A. Pulmonary function abnormalities after allogeneic marrow transplantation: a systematic review and assessment of an existing predictive instrument. Bone Marrow Transplant 2002;30:599-607.
45. Alidina A. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: associated with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999;5:322-327.
46. Alidina A, Lawrence D, Ford LA, et al. Thiotepa-associated cardiomyopathy during blood or marrow transplantation: association with the female sex and cardiac risk factors. Biol Blood Marrow Transplant 1999;5:322-327.
47. Leahey AM, Teunissen H, Friedman DL, Moshang T, Lange BJ, Meadows AT. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999;32:163-169.
48. Lonnerholm G, Arvidson J, Andersson LG, Carlson K, Jonzon A, Sunnegardh J. Myocardial function after autologous bone marrow transplantation in children:a prospective long-term study.Acta Paediatr 1999;88:186-192.
49. Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol 1995;15:473-479.
50. Paller MS. Bone marrow transplantation nephropathy. J Lab Clin Med 1994;124:315-317.
51. Moulder JE, Fish BL, Cohen EP. ACE inhibitors and All receptor antagonists in the treatment and prevention of bone marrow transplant nephropathy. Curr Pharm Des 2003;9:737-749.
52. Bleggi-Torres LF, de Medeiros BC, Ogasawara VS, et al.latrogenic Wernicke's encephalopathy in allogeneic bone marrow transplantation: a study of eight cases. Bone Marrow Transplant 1997;20:391-395.
53. Davies SM, Szabo E, Wagner JE, Ramsay NK, Weisdorf DJ.Idiopathic hyperammonemia:a frequently lethal complication of bone marrow transplantation. Bone Marrow Transplant 1996;17:1119-1125.
54. Krouwer H. Neurologic complications of bone marrow transplantation. Neurol Clin N Am 2003;21:379-352.
55. Colosimo M, McCarthy N, Jayasinghe R, Morton J, Taylor K, Durrant S. Diagnosis and management of subdural haematoma complicating bone marrow transplantation. Bone Marrow Transplant 2000;25:549-552.
56. Coplin WM, Cochran MS, Levine SR, Crawford SW. Stroke after bone marrow transplantation: frequency, aetiology and outcome. Brain 2001;124(pt 5):1043-1051.
57. Wen PY, Alyea EP, Simon D, Herbst RS, Soiffer RJ, Antin JH. Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology 1997;49:1711-1714.
58. Mackey JR, Desai S, Larratt L, Cwik V, Nabholtz JM. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant 1997;19:939-942.
59. Zaja F, Russo D, Fuga G, Perella G, Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000;55:1062-1063.